drugset / Trial / NCT05070728

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

NCT05070728

Phase 3 Terminated 12 enrolled EyePoint Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.

Timeline

Start
2021-10-13
Primary completion
2023-04-12
Completion
2023-04-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator fluocinolone acetonide Small molecule 0.05 mg Intravitreal